Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Uncovering the antioxidative potential of paroxetine in hyperglycemic conditions

April 9, 2013

In vivo results suggest HIS-601 is a promising candidate for metabolic disorders

April 8, 2013

Aspireo reports encouraging results from phase IIa study of somatoprim in acromegaly

April 5, 2013

Transfer of rights to exenatide completed in Japan

April 5, 2013

Long-term results show sapropterin is safe and well tolerated in pediatric patients with PKU

April 4, 2013

Dainippon Sumitomo gains rights to two Edison Pharmaceuticals compounds

April 4, 2013

Protalix BioTherapeutics treats first patient in phase I study of PRX-112

April 4, 2013

Regenx Biosciences Consortium receives European Commission grant for rare disease

April 4, 2013

BioMarin submits Vimizim BLA to FDA

April 3, 2013

FDA approves Quartette for the prevention of pregnancy

April 3, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 15, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...